VFA
BCYC

Valeo Financial Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Valeo Financial Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6
Closed – – 1635
2020
Q2 		$0 Buy
+6
New +$92 ﹤0.01% 2029

Other funds holding BCYC

TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Valeo Financial Advisors's BCYC Position: Q3 2020 in Review

Valeo Financial Advisors sold out of Bicycle Therapeutics (BCYC) in Q3 2020, closing a stake of 6 shares.

Valeo Financial Advisors first reported a position in BCYC in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 18 funds tracked by Wall St. Rank hold BCYC as of Q3 2020.

  • Valeo Financial Advisors reported no remaining Bicycle Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Valeo Financial Advisors sold 6 Bicycle Therapeutics shares in Q3 2020.
  • Valeo Financial Advisors first reported a position in Bicycle Therapeutics in Q2 2020 and held it in 1 quarter.
  • Valeo Financial Advisors's Bicycle Therapeutics position peaked at $0 in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2020.

Based on Valeo Financial Advisors's 13F filing for Q3 2020, filed 28 Oct 2020.